Specifically, administration of either anti-PD-1 or anti-PD-L1 antibody was shown to reduce brain pathology and improve cognitive performance in various mouse models of Alzheimer’s disease [8–12]. This evidence concerns the gene CD274 and early-onset autosomal dominant Alzheimer disease.